Technical Analysis for LPCN - Lipocine Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Up | Up | Up |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| 20 DMA Resistance | Bearish | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Gapped Down | Weakness | 0.00% | |
| 20 DMA Resistance | Bearish | -3.19% | |
| Shooting Star Candlestick | Bearish | -3.19% | |
| Lizard Bearish | Bearish Day Trade Setup | -3.19% | |
| NR7 | Range Contraction | -3.19% | |
| Narrow Range Bar | Range Contraction | -3.19% | |
| Wide Bands | Range Expansion | -3.19% | |
| Gapped Up | Strength | -3.19% |
| Alert | Time |
|---|---|
| 20 DMA Resistance | about 18 hours ago |
| Rose Above 20 DMA | about 19 hours ago |
| Up 3% | about 19 hours ago |
| Up 2% | about 19 hours ago |
| Up 1% | about 19 hours ago |
Free Daily (Stock) Chart Reading
- Earnings date: 05/09/2024
Lipocine Inc. Description
Lipocine Inc., a specialty pharmaceutical company, is engaged in the development of pharmaceutical products in the areas of men's and women's health. The company offers a portfolio of proprietary product candidates that are used to produce pharmacokinetic characteristics; facilitate lower dosing requirements and bypass first-pass metabolism; reduce side effects; and eliminate gastrointestinal interactions that limit bioavailability. Its product candidates for men's health include LPCN 1021, an oral product candidate, which is in Phase III clinical trials; and LPCN 1111, an oral product candidate that is in Phase I/II clinical trials for the treatment of testosterone replacement therapy. The company's product candidates for women's health comprise LPCN 1107, which is in Phase I/II clinical trials for the prevention of preterm birth. Lipocine Inc. was founded in 1997 and is headquartered in Salt Lake City, Utah.
Classification
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Keywords: Pharmaceutical Alcohol Pharmaceutical Products Gastrointestinal Clinical Research Clinical Trial Metabolism Bypass Ketones Testosterone Androstanes Preterm Birth
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 7.15 |
| 52 Week Low | 2.3101 |
| Average Volume | 78,500 |
| 200-Day Moving Average | 3.72 |
| 50-Day Moving Average | 4.69 |
| 20-Day Moving Average | 5.01 |
| 10-Day Moving Average | 4.76 |
| Average True Range | 0.42 |
| RSI (14) | 49.75 |
| ADX | 15.78 |
| +DI | 22.28 |
| -DI | 18.55 |
| Chandelier Exit (Long, 3 ATRs) | 5.89 |
| Chandelier Exit (Short, 3 ATRs) | 5.66 |
| Upper Bollinger Bands | 5.94 |
| Lower Bollinger Band | 4.08 |
| Percent B (%b) | 0.41 |
| BandWidth | 37.09 |
| MACD Line | -0.02 |
| MACD Signal Line | 0.01 |
| MACD Histogram | -0.0283 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 5.36 | ||||
| Resistance 3 (R3) | 5.42 | 5.30 | 5.27 | ||
| Resistance 2 (R2) | 5.30 | 5.17 | 5.27 | 5.25 | |
| Resistance 1 (R1) | 5.08 | 5.09 | 5.02 | 5.02 | 5.22 |
| Pivot Point | 4.96 | 4.96 | 4.93 | 4.93 | 4.96 |
| Support 1 (S1) | 4.74 | 4.83 | 4.68 | 4.68 | 4.48 |
| Support 2 (S2) | 4.62 | 4.75 | 4.60 | 4.45 | |
| Support 3 (S3) | 4.40 | 4.62 | 4.43 | ||
| Support 4 (S4) | 4.34 |
